Spineart secures CHF 25 million capital increase to accelerate global…

Team S · 2025-10-11T07:18:57.000Z

Spineart, a Geneva-based medtech company developing spinal implants and related surgical technologies, completed a CHF 25 million capital increase backed by long-standing shareholders Gimv and EGS Beteiligungen (EGSB). The investment is intended to support Spineart’s global expansion, advance its product pipeline (including work on devices such as the BAGUERA® C cervical disc), and pursue regulatory approvals in markets including the U.S. Key investors: Gimv and EGS Beteiligungen (EGSB). Founders/key people: . Funding round type: capital increase/growth financing. Valuation: . Stated use of funds: accelerate global expansion, product and innovation development, and regulatory activities.

Member Login Get Access

Spineart secures CHF 25 million capital increase to accelerate global… | Newnex